AbbVie Stock’s Growth Story Has One Question Mark

The company’s post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.

For an AbbVie (ABBV) shareholder, the last few years have been a masterclass in navigating a patent cliff. The company has successfully transitioned from its reliance on the megablockbuster Humira to a new era powered by its key drugs: Skyrizi and Rinvoq. The headline numbers are strong, and the stock is trading near its highs. But beneath the surface, there is a number that warrants your attention, not because it’s a setback, but because of what it might signal.

That number is the growth rate for Rinvoq.

A Deceleration Hiding in Plain Sight

In the most recent quarter, Rinvoq’s global sales grew 20.2% year-over-year. On its own, that is a fantastic figure for a multi-billion-dollar product. The concern comes from the comparison. That 20.2% growth represents a slowdown from the 28.6% operational growth rate the drug posted in the prior quarter. While a data point is not a trend, a deceleration of this magnitude in a key growth asset is a yellow flag. It’s the kind of subtle shift that an investor focused only on total revenue might miss, but it’s precisely where risk can hide.

Why A Pillar’s Pace Matters So Much

AbbVie’s investment case rests on the powerful punch of Skyrizi and Rinvoq. Skyrizi is still accelerating, posting an impressive 29.2% growth. But the strategy requires both pillars to be exceptionally strong to drive the top-tier growth the market expects. If Rinvoq’s growth has found a lower gear, it puts significantly more pressure on Skyrizi to outperform. This is the first concrete data point that gives life to the market’s background worry: an intensifying competitive landscape in immunology. A slowdown, even a modest one, could be the first sign that new rivals are beginning to make an impact on a core AbbVie asset.

What’s Riding On Rinvoq’s Re-acceleration

The stakes are high. Rinvoq is on track for global sales of $10.2 billion this year, making it a vital part of AbbVie’s roughly $67.3 billion in expected total revenue. More importantly, it’s a cornerstone of the growth that supports the stock’s valuation. With the share price near its high, the market appears to be pricing in a continuation of stellar, multi-faceted growth. A sustained deceleration in a product as critical as Rinvoq could challenge those assumptions and force a reassessment of the company’s long-term growth trajectory.

The question for investors isn’t whether 20.2% growth is good. It is. The question is whether this is a temporary dip or the start of a new, slower trend. Your answer to that will likely determine how the market views AbbVie’s next act.

Don’t Bet It All On One Number

That is the risk of owning any single stock: your outcome rests on one company getting it right. You do not have to concentrate risk that way. Rather than depend on AbbVie alone, the Trefis High Quality (HQ) Portfolio spreads exposure across 30 high-quality stocks and re-balances them with discipline, so that no single name carries an outsized share of your returns, and it has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. If the risk we just walked through gives you pause, a diversified alternative like this is worth a serious look.